The role of oncology nurses and APPs in research is largely to stay abreast of trials that may be useful to patients and recommend them whenever possible, according to Erica Doubleday, MS, FNP-C, BSN, ...

Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, ...

New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal ...

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d ...

While lower relative dose intensity of docetaxel was associated with higher rates of G-CSF use and more adverse events, ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

Dr Mohan discusses with Nurse Goff, Dr Mohan, and Dr Nadeem strategies for maintaining continuity of care and communication between community centers and academic institutions during bispecific ...

Dr Mohan discusses with Dr Nadeem, Dr Mann, and Nurse Distaso the key factors for referring patients from community centers to academic institutions for bispecific therapy and strategies for ...

Improved progression-free survival in metastatic urothelial carcinoma was observed in patients experiencing neuropathy, skin rash, and hyperglycemia following enfortumab vedotin.

Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.